High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19

Paula M. Martins BSc1 | Tatyanne L. N. Gomes MSc2 | Emanoelly P. Franco BSc1 | Liana L. Vieira BSc1 | Gustavo D. Pimentel PhD2

1 Clinical Hospital, Federal University of Goiás, Goiânia, Goiás, Brazil
2 Faculty of Nutrition, Federal University of Goiás, Goiânia, Goiás, Brazil

Abstract

Background: Inflammation plays a crucial role in nutrition status and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in intensive care unit (ICU) patients with COVID-19.

Methods: Patients with confirmed COVID-19 and ICU admission were enrolled in a retrospective, observational, cross-sectional study. The medians of C-reactive protein (CRP; ≥13.8 mg/dl) and the neutrophil-to-lymphocyte ratio (NLR; ≥12.6) upon admission were used to dichotomize patients.

Results: Of the 73 patients, 63% were men; the average age was 56 years, and the median length of hospital stay was 10 (25th: 4; 75th: 17) days. When nutrition risk screening tools were used, 85% were at risk according to Nutritional Risk Screening (≥3 points), whereas 42% had high risk according to the Modified Nutrition Risk in the Critically Ill (mNUTRIC; ≥5 points), and 57% were moderately or severely malnourished according to the Subjective Global Assessment (B or C). Mortality was higher in the group with NLR ≥12.6 than in the group with NLR <12.6, with no difference between CRP groups. A significant association was found only between NLR and mNUTRIC, even when adjusted by sex, age, and body mass index (odds ratio, 1.36; 95% CI, 1.06–1.76; P = 0.016), but not between CRP and nutrition risk.

Conclusion: Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score).

Keywords
COVID-19, ICU, inflammation, nutrition status

Clinically Relevant Statement

Inflammation plays a crucial role in nutrition status and clinical outcomes and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Considering that chronic disease increases COVID-19–induced complications, that the mortality rate of this study is 50.6% of patients, and that inflammation is critical to nutrition status, our study highlights the importance of evaluating the neutrophil-to-lymphocyte ratio as a key marker in the screening of nutrition risk in the intensive care unit in patients hospitalized with COVID-19.
INTRODUCTION

The World Health Organization (WHO) has named coronavirus disease 2019 (COVID-19) the disease caused by SARS-CoV-2. COVID-19 was declared a pandemic in March 2020 because of its high degree of infectiousness and has become a global health threat.1 The virus spreads via droplets and aerosols released through the airways and is transmitted directly by contact or by air, with an incubation period of 2–14 days.2–4 Although the most severe forms of COVID-19 have been described at all ages, several studies suggest that older patients and individuals with comorbidities have higher mortality rates.5–8 Invasion and replication of the SARS-CoV-2 virus in host cells promote cell damage that induces pyroptosis, stimulating a high degree of local inflammation and increased secretion of proinflammatory cytokines at the systemic level.9,10 In more-severe cases, there is a higher concentration of inflammatory cytokines caused by hypersensitization of the immune system in response to viral infection and secondary infections.11 It is evident that inflammation plays a crucial role in clinical outcomes in patients with COVID-19.10 Thus, the assessment of severity markers, such as D-dimer, C-reactive protein (CRP), ferritin, and the neutrophil-to-lymphocyte ratio (NLR), are important in the screening and monitoring of clinical outcomes.12

Likewise, considering the relationship between the elevated systemic inflammatory state and protein catabolism in intensive care unit (ICU) patients, nutrition assessment and therapy are fundamental parts of the comprehensive and multiprofessional care of patients who are critically ill with COVID-19, given the positive association between high nutrition risk and worse clinical outcomes.13–15 Early assessment of nutrition status is essential for producing and executing therapeutic care plans, avoiding the worsening of nutrition status, and improving clinical outcomes.16,17 However, because of the heterogeneity of the clinical profiles of patients who are critically ill with COVID-19 and the metabolic changes that affect them, little is known about the use of existing nutrition risk assessment instruments validated for the general ICU public.18

Hu et al suggested that all ICU patients with COVID-19 should be screened early for nutrition risk by using validated tools, including the Nutritional Risk Screening (NRS) or Modified Nutrition Risk in the Critically Ill (mNUTRIC).19 In addition, nutrition assessment tools have been suggested, such as the Subjective Global Assessment (SGA) and the Global Leadership Initiative on Malnutrition (GLIM).20 Zhang et al used the mNUTRIC to screen nutrition risk in patients who are critically ill with COVID-19 and observed a strong relationship between high nutrition risk and mortality.18

Therefore, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in ICU patients with COVID-19. Our hypothesis is that NLR and CRP are associated with the NRS, SGA, and mNUTRIC instruments and thus can be useful in clinical practice in the nutrition screening of patients who are critically ill with COVID-19.

METHODS

Study design and participants

This was a retrospective, observational cross-sectional study conducted at a university hospital in the midwestern region of Brazil. This study was approved by the Research Ethics Committee of Hospital das Clínicas, Universidade Federal de Goiás (number 4.381.491).

The study included patients with suspected COVID-19 who were in critical condition, admitted to ICUs, 18 years or older, of both sexes. The following were excluded: patients with negative results in a reverse transcriptase–polymerase chain reaction test and those who did not have the available data on blood concentrations of CRP or white blood cell counts.

A convenience sample was established from March 2020 to October 2020, in which 88 patients who met the inclusion criteria were selected. Of these, 15 were excluded because their medical records contained incomplete data. Thus, 73 patients were included and analyzed (Figure 1).

Data collection

The information was collected from medical records during the consultations performed at the surgical ICU and COVID-19 ICU. Data from the first 48 h of admission to the ICU were used.

Sociodemographic data (sex and age), anthropometric data (body weight and height), nutrition data (NRS 2002 and SGA), clinical data (length of ICU stays and mortality), presence of comorbidities (cancer, chronic obstructive pulmonary disease, cardiac insufficiency, chronic kidney disease, obesity, type 2 diabetes mellitus, and systemic arterial hypertension), prognostic indexes (Acute Physiology and Chronic Health Evaluation II [APACHE II],11 Sepsis-Related Organ Failure Assessment [SOFA],21 and mNUTRIC,22 type of ventilation during hospitalization (mechanical ventilation [MV]), blood CRP concentrations, neutrophil and lymphocyte count, and D-dimer levels were collected.
To obtain NLR, the absolute blood neutrophil count was calculated by adding the rod-shaped and segmented neutrophils and was then divided by the absolute blood lymphocyte count. The biochemical method used to quantify serum concentrations of neutrophils and lymphocytes was the CELL-DYN Ruby automated hematology analyzer and microscopy. CRP concentrations were quantified by the biochemical immunoturbidimetric method.

In assessing the nutrition status, the body mass index (BMI) was used, dividing body weight (kilograms) by height (meters) squared. Nutrition risk was obtained by using the NRS 2002;28 patients with a score of <3 were considered as being not at nutrition risk, and those with a score of ≥3 were considered as being at nutrition risk. In addition, the mNUTRIC tool,27 which excludes interleukin 6 (IL-6) levels, was also used to identify critically ill patients at risk of unfavorable outcomes that can be modified by aggressive nutrition intervention, in which scores of <4 were considered predictors of low risk and scores of ≥5, predictors of high risk. Regarding the nutrition diagnosis, the SGA result was taken into account as follows: nourished (A), moderately malnourished (B), and severely malnourished (C).18–20 The SGA is a tool routinely performed by a trained nutritionist in patients who are critically ill with COVID-19 and in the hospital.

The patients were dichotomized by using the sample median results for NLR and CRP concentrations, because there is still no consensus in the literature on these cutoff points in patients critically ill with COVID-19. The results were 12.6 for NLR and 13.8 mg/dl for CRP. NLR values above or equal to the median (12.6) were classified as indicators of high inflammation. Likewise, CRP concentrations above or equal to the median (13.8 mg/dl) were classified as indicators of high inflammation.

**Statistical analyses**

Descriptive statistical analysis was performed with a cutoff point of 12.6 for NLR and 13.8 mg/dl for CRP. The data were tabulated in an Excel spreadsheet, and then, the normality test was performed by using the Kolmogorov-Smirnov test. Normal variables were presented as mean ± SD and nonnormal values as median, minimum, and maximum.

Categorical data were presented as absolute (n) and relative (%) values. For comparisons of means, Student t-test was performed in the presence of normally distributed data, and the Mann-Whitney U test was performed for data that did not show a normal distribution. Logistic regression analysis was performed to verify the presence of an association between the variables mNUTRIC, NRS, and SGA (continuous data as independent variables) and the systemic inflammation markers NLR and CRP (categorical data as a dependent variable).

The variables related to nutrition status were analyzed as continuous numbers, and the data were presented in the crude model and adjusted for age, BMI, and sex (model 1). The regression results are presented as odds ratios (ORs) and 95% CIs. The MedCalc software (version 11.1.1.0) was used for all analyses, and results were considered statistically significant at P < 0.05.

**RESULTS**

The sample (n = 73) had a mean age of 56 years and was mostly composed of men (63%). The median number of days in the COVID-19 ICU was 10 (25th percentile: 4; 75th percentile: 17), and mortality was 50.6%. The most frequent comorbidity among patients was hypertension (49.3%), followed by obesity (41%) and diabetes (30%). The mean duration of MV was 13.4 ± 8.3 days, the mean BMI was 29, and 23.3% of patients were obese (BMI ≥ 30).

Of the total, 50.6% of patients died during hospitalization, 85% presented nutrition risk with NRS ≥ 3, 42% had high risk with NUTRIC ≥ 5, and 57% were moderately or severely malnourished according to SGA (B or C).

When patients were dichotomized according to the medians of NLR and blood CRP concentration, higher mortality, longer MV in the first 24 h in the ICU, and higher APACHE, SOFA, mNUTRIC, and NRS scores were observed in patients with NLR ≥ 12.6. In addition, those in the group with NLR ≥ 12.6 also had lower BMI when compared with that of patients with low NLR (<12.6) (Table 1). When patients were dichotomized according to CRP, differences between the two groups regarding the nutrition status variable SGA were found. However, it is interesting to note that severely malnourished patients were not observed in the group with CRP ≥ 13.8 mg/dl. Additionally, patients in the group with CRP ≥ 13.8 mg/dl tended to have higher BMI than those in the group with low CRP (Table 2).

In logistic association analyses, NLR was positively associated with mNUTRIC in the crude model and model 1 when adjusted for age, sex, and BMI (OR, 1.36; 95% CI, 1.06–1.76; P = 0.016) (Table 3). However, CRP was not associated with any of the nutrition risk assessment variables (mNUTRIC, SGA, and NRS) (Table 4).

**DISCUSSION**

Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score), which may be important in determining nutrition risk in patients who are critically ill with COVID-19. One hypothesis for this result is that the mNUTRIC score evaluates in more detail variables of inflammation and disease severity when compared with the NRS and SGA tools, which evaluate predominantly nutrition variables. CRP was not associated with tools that screen for nutrition risk or nutrition assessment for the diagnosis of malnutrition (NRS and SGA, respectively). A possible explanation for this is that, according to Li and Chan, blood levels change rapidly because of various acute-phase factors related to infectious or inflammatory activity or tissue damage and are not necessarily associated with the immune response and nutrition risk, as NLR was shown to be in this study. Although CRP participates in innate immunity, there are no reports of decreases in its values and participation in the reduction in the immune response. In addition, according to Aguilar et al, CRP has a plasma half-life of 19 h and can remain high for several days, even in the absence of stimuli. For this scenario.
**TABLE 1** Data of patients admitted to the ICU according to NLR classification

| Variables                                      | NLR < 12.6 (n = 36) | NLR ≥ 12.6 (n = 36) | P       |
|------------------------------------------------|----------------------|---------------------|---------|
| Sex (n = 72), n (%)                             |                      |                     | 1.00    |
| Male                                           | 23 (63.8)            | 22 (61.2)           |         |
| Female                                         | 13 (36.2)            | 14 (38.8)           |         |
| Age, mean ± SD, years                          | 53.4 ± 15.0          | 58.4 ± 18.6         | 0.11    |
| Length in ICU, median (25th–75th), days        | 6.5 (3.2–11.0)       | 12 (5–19.5)         | 0.34    |
| Mortality (n = 72), n (%)                       |                      |                     | 0.004*  |
| Alive                                          | 24 (66.6)            | 11 (30.5)           |         |
| Died                                           | 12 (33.3)            | 25 (69.5)           |         |
| Comorbidities (n = 72), n (%)                  |                      |                     | 0.66    |
| Cancer                                         | 3 (8.3)              | 6 (16.6)            |         |
| COPD                                           | 5 (18.8)             | 7 (19.4)            |         |
| Insufficiency cardiac                          | 3 (8.3)              | 4 (11.1)            |         |
| Chronic kidney disease                         | 5 (18.8)             | 5 (18.8)            |         |
| Diabetes                                       | 12 (33.3)            | 10 (27.7)           |         |
| Obesity (BMI ≥ 30)                             | 20 (55.5)            | 10 (27.7)           |         |
| Hypertension                                   | 18 (50.0)            | 18 (50.0)           |         |
| No                                             | 4 (11.1)             | 5 (18.8)            |         |
| APACHE II, mean ± SD, score                    | 14.9 ± 9.7           | 22.1 ± 10.7         | 0.002*  |
| SOFA, mean ± SD, score                         | 5.4 ± 5.1            | 8.4 ± 4.7           | 0.01*   |
| Mechanical ventilation (n = 72), n (%)         |                      |                     | 0.004*  |
| No                                             | 25 (69.5)            | 13 (36.1)           |         |
| Yes                                            | 11 (30.5)            | 23 (63.9)           |         |
| Mechanical ventilation duration, mean ± SD, days| 13.5 ± 8.9           | 13.3 ± 8.3          | 0.48    |
| BMI, mean ± SD                                 | 30.6 ± 6.6           | 27.5 ± 5.9          | 0.02*   |
| mNUTRIC, mean ± SD, score                      | 3.4 ± 2.3            | 5.2 ± 2.5           | 0.002*  |
| mNUTRIC (n = 72), n (%)                        |                      |                     | 0.15    |
| Low risk (1–4)                                 | 24 (66.6)            | 17 (47.3)           |         |
| High risk (≥ 5)                                | 12 (33.7)            | 19 (52.7)           |         |
| Nutrition risk screening, mean ± SD, score     | 3.5 ± 1.2            | 4.1 ± 1.2           | 0.03*   |
| Nutrition risk screening (n = 72), n (%)       |                      |                     | 0.47    |
| No risk                                        | 6 (16.7)             | 3 (8.3)             |         |
| With risk                                      | 30 (83.3)            | 33 (91.7)           |         |
| Subjective Global Assessment (n = 72), n (%)   |                      |                     | 0.26    |
| Well-nourished (A)                             | 18 (50)              | 12 (33.3)           |         |
| Moderately malnourished (B)                    | 17 (47.3)            | 21 (58.4)           |         |
| Severely malnourished (C)                      | 1 (2.7)              | 3 (8.3)             |         |
| Biochemical analysis                           |                      |                     |         |
| Hematocrit, mean ± SD, %                       | 37.0 ± 8.2           | 37.4 ± 8.0          | 0.40    |
| Hemoglobin, mean ± SD, g/dl                    | 12.0 ± 2.7           | 12.1 ± 2.6          | 0.43    |
| C-reactive protein, median (25th–75th), mg/dl | 6.0 (3.0–12.0)       | 7.0 (4.5–21.0)      | 0.01*   |
| D-dimer, median (25th–75th), ng/ml             | 610.0 (277–899)      | 820.0 (422–1528)    | 0.46    |
| NLR, median (25th–75th)                        | 11 (6–41.5)          | 31 (16–65.7)        | <0.0001 |

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; 25th, percentile 25th; 75th, percentile 75th; mNUTRIC, Modified Nutrition Risk in the Critically Ill; NLR, neutrophil-to-lymphocyte ratio; SOFA, Sepsis-Related Organ Failure Assessment.

*P < 0.05 was considered as significant.
### TABLE 2  Data of patients admitted to the ICU according to CRP classification

| Variables                        | CRP < 13.8 mg/dl (n = 36) | CRP ≥ 13.8 mg/dl (n = 37) | P  |
|----------------------------------|---------------------------|---------------------------|----|
| Sex (n = 73), n (%)              |                           |                           | 0.37 |
| Male                             | 25 (69.5)                 | 21 (56.7)                 |    |
| Female                           | 11 (30.5)                 | 16 (43.3)                 |    |
| Age, mean ± SD, years            | 58.6 ± 16.3               | 53.4 ± 15.4               | 0.09 |
| Length in ICU, median (25th–75th), days | 8 (3.2–11)               | 12 (5–18.5)               | 0.40 |
| Mortality (n = 73), n (%)        |                           |                           | 0.72 |
| Alive                            | 19 (52.7)                 | 17 (46.0)                 |    |
| Died                             | 17 (47.3)                 | 20 (54.0)                 |    |
| Comorbidities (n = 73), n (%)    |                           |                           | 0.72 |
| Cancer                           | 5 (13.8)                  | 4 (10.8)                  |    |
| COPD                             | 9 (25.0)                  | 3 (8.1)                   |    |
| Insufficiency cardiac            | 5 (13.8)                  | 2 (5.4)                   |    |
| Chronic kidney disease           | 5 (13.8)                  | 5 (13.5)                  |    |
| Diabetes                         | 12 (33.3)                 | 10 (27.0)                 |    |
| Obesity (BMI ≥ 30)               | 14 (38.8)                 | 16 (43.2)                 |    |
| Hypertension                     | 18 (50.0)                 | 18 (48.6)                 |    |
| No                               | 5 (13.8)                  | 4 (10.6)                  |    |
| APACHE II, mean ± SD, score      | 17.9 ± 11.2               | 18.8 ± 10.5               | 0.36 |
| SOFA, mean ± SD, score           | 6.3 ± 5.0                 | 7.3 ± 5.2                 | 0.21 |
| Mechanical ventilation (n = 73), n (%) | 36 (100)               | 36 (97.2)                 |    |
| No                               | 0 (0)                     | 1 (2.8)                   |    |
| Mechanical ventilation duration, mean ± SD, days | 13.4 ± 8.5               | 13.4 ± 8.5               | 0.49 |
| BMI, mean ± SD                   | 27.9 ± 6.0                | 30.0 ± 6.6                | 0.07 |
| mNUTRIC, mean ± SD, score        | 4.2 ± 2.9                 | 4.3 ± 2.3                 | 0.43 |
| mNUTRIC (n = 73), n (%)          |                           |                           | 0.91 |
| Low risk (1–4)                   | 20 (55.5)                 | 22 (59.4)                 |    |
| High risk (≥5)                   | 16 (44.5)                 | 15 (40.6)                 |    |
| Nutrition risk screening, mean ± SD, score | 3.7 ± 1.4               | 3.9 ± 1.1                 | 0.25 |
| Nutrition risk screening (n = 73), n (%) | 7 (19.4)               | 4 (810.8)                 |    |
| No risk                          | 29 (80.6)                 | 33 (89.1)                 |    |
| With risk                        |                           |                           | 0.02 |
| Subjective Global Assessment (n = 73), n (%) | 18 (50.0)               | 13 (35.2)                 |    |
| Well-nourished (A)               | 14 (38.8)                 | 24 (64.8)                 |    |
| Moderately malnourished (B)      |                           |                           |    |
| Severely malnourished (C)        | 4 (11.2)                  | 0 (0)                     |    |
| Biochemical analysis             |                           |                           |    |
| Hematocrit, mean ± SD, %         | 37.7 ± 7.0                | 36.8 ± 9.0                | 0.33 |
| Hemoglobin, mean ± SD, g/dl      | 12.3 ± 2.3                | 12.0 ± 3.0                | 0.28 |
| CRP, median (25th–75th), mg/dl   | 5 (2.7–7.2)               | 16 (6–24)                 | <0.0001 |
| D-dimer, median (25th–75th), ng/ml | 407.5 (140–701.7)       | 898 (438.7–2154.2)       | 0.054 |
| Neutrophil-to-lymphocyte ratio, median (25th–75th) | 15.5 (7.7–48.5)       | 28 (12–47.7)              | 0.14 |

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ICU, intensive care unit; 25th, percentile 25th; 75th, percentile 75th; mNUTRIC, Modified Nutrition Risk in the Critically Ill; SOFA, Sepsis-Related Organ Failure Assessment.

*P < 0.05 was considered as significant.
TABLE 3  Association between NLR and nutrition risk variables in patients with COVID-19 admitted to the intensive care unit

| Variables | OR (95% CI) | P   |
|-----------|-------------|-----|
| NLR × mNUTRIC |            |     |
| Crude  | 1.34 (1.09–1.64) | 0.005* |
| M1     | 1.36 (1.06–1.76)  | 0.016 |
| NLR × SGA |            |     |
| Crude  | 1.95 (0.85–4.44)  | 0.11 |
| M1     | 1.25 (0.46–3.36)  | 0.65 |
| NLR × NRS |            |     |
| Crude  | 1.47 (0.96–2.26)  | 0.07 |
| M1     | 1.23 (0.77–1.97)  | 0.36 |

Note: NLR was entered as a categorical variable (dependent), and mNUTRIC, SGA, and NRS were entered as continuous variables (independent). M1: adjusted by age, body mass index, and sex.

Abbreviations: M1, model 1; mNUTRIC, Modified Nutrition Risk in the Critically Ill; NLR, neutrophil-to-lymphocyte ratio; NRS, Nutritional Risk Screening; OR, odds ratio; SGA, Subjective Global Assessment.

*P < 0.05 was considered as significant.

TABLE 4  Association between CRP and nutrition risk variables in patients with COVID-19 admitted to the intensive care unit

| Variables | OR (95% CI) | P   |
|-----------|-------------|-----|
| CRP × mNUTRIC |            |     |
| Crude  | 1.01 (0.84–1.21) | 0.86 |
| M1     | 1.18 (0.92–1.50)  | 0.17 |
| CRP × SGA |            |     |
| Crude  | 1.11 (0.50–2.44)  | 0.78 |
| M1     | 1.84 (0.68–4.94)  | 0.22 |
| CRP × NRS |            |     |
| Crude  | 1.14 (0.78–1.67)  | 0.49 |
| M1     | 1.45 (0.91–2.31)  | 0.11 |

Note: CRP was entered as a categorical variable (dependent), and mNUTRIC, SGA, and NRS were entered as continuous variables (independent). M1: adjusted by age, body mass index, and sex.

Abbreviations: CRP, C-reactive protein; M1, model 1; mNUTRIC, Modified Nutrition Risk in the Critically Ill; NRS, Nutritional Risk Screening; OR, odds ratio; SGA, Subjective Global Assessment.

reason, monitoring dosages over a period of days is more useful than isolated results.32 In the present study, we did not find any severely malnourished patients in the group with CRP ≥ 13.8 mg/dl. Indeed, CRP levels are not linearly correlated with nutrition status,33 suggesting that during high-grade inflammation, as in infection by COVID-19, the nutrition status may be modulated by other cytokines rather than by CRP levels. Considering that patients in the group with CRP ≥ 13.8 mg/dl tended to have higher BMI than those in the group with low CRP, overweight has been suggested to explain the absence of malnourished patients in the group with high inflammation when measured by CRP.

The inflammatory response plays a fundamental role in the clinical manifestations of COVID-19.10,34–37 During infection, SARS-CoV-2 initiates cell infection by binding to the angiotensin-converting enzyme 2 on the surface of human cells, triggering complex molecular events that lead to high-grade inflammation. Antigen-presenting cells are also infected, leading to the activation, differentiation, and subsequent release of more proinflammatory cytokines.10,34 The virus’s ability to infect T cells causes a decrease in T lymphocytes and an increase in cytokine concentration, thus increasing lymphocytic apoptosis and causing deleterious organic effects and, consequently, greater disease severity.13,38,39 Qin et al observed that severe cases of COVID-19 have elevated NLRs compared with those of patients with less-severe COVID-19, in which the neutrophil count tends to be higher and the lymphocyte count lower.40

Inflammation, nutrition status, and severity in critically ill patients are variables that are widely correlated in the literature; the importance of inflammation and disease severity is well elucidated in the characterization of nutrition risk.7,9,17,41 Likewise, critically ill patients at high nutrition risk should be identified early, as this condition is directly associated with worse clinical outcomes.30 When identified as being at high nutrition risk, patients can benefit from nutrition interventions.52 The systemic inflammation marker NLR can assist in determining this risk because it is associated with the mNUTRIC score, as observed in this study. In agreement with our findings, a previous review and meta-analysis highlighted the NLR as an imperative marker of prognosis for patients with COVID-19.52 In addition, elevated NLR values on hospital admission are linked to mortality and severity of COVID-19.44,45

Although the modified form of the NUTRIC score, which excludes IL-6, has been validated, several studies seek to simplify it by replacing IL-6 with more-available variables, such as CRP.46 The measurement of IL-6 concentrations is not common during the hospital clinical practice, which makes the NUTRIC tool difficult to use in its original form. Likewise, at present, we observed that NLR was related to the mNUTRIC, so it is a promising marker to be studied as a more accessible version to replace the quantification of IL-6. NLR can be calculated in a simple manner by using the white blood cell count, an examination widely available in health services.35 In this sense, evidence suggests that NLR is a reliable and sensitive marker, as it encompasses the triad immunoinflammatory response, neuroendocrine stress, and disease severity. It can be used to measure stress, intensity of infection, inflammation, and COVID-19 outcomes.52,42

There is no consensus on cutoff points for the variables NLR and CRP in patients critically ill with COVID-19. Our sample had a median of 12.6 for NLR and 13.8 mg/dl for CRP. In patients diagnosed with COVID-19, Zeng et al47 found the sensitivity of NLR ≥ 2.6 to predict the worsening of the disease. Moreover, another study also showed that patients with COVID-19 had a median NLR of 2.5 (25th percentile: 1.7; 75th percentile: 3.7),48 and Song et al observed that critically ill patients had NLR values ≥ 5.0.53 A possible reason why the NLR values are higher than those in the other studies is the mortality rate found in our study—in particular, in the group with high NLRs—because the risk of in-hospital mortality may be 8% higher for every unit increase in NLR.50
Although the present study is pioneering for investigating the relationship between the NLR and SGA, NRS, and mNUTRIC, a recent study found an association between NLR values and the prognostic nutrition index in patients with severe COVID-19. Thus, further studies are warranted to investigate NLR levels with other nutrition risk screening and nutrition assessment tools.

Limitations and strengths

The present study has some limitations: (1) a low number of patients were included in the study; (2) there is a lack of consensus on the cutoff point in the literature on NLR and CRP for this population; (3) the study design does not allow for the establishment of a cause-and-effect relationship; and (4) these tools for assessing nutrition risk should be interpreted with caution because the inherent effect of disease-associated inflammation depends on nutrition adequacy, utilization, and assimilation. As positive points, (1) we emphasize that it is a study that used accessible variables and is easy to apply in clinical hospital practice at low cost, and (2) it is the first study associating the NLR with a nutrition risk tool (mNUTRIC score) in ICU patients with COVID-19, which reinforces the need for further studies in the area.

CONCLUSIONS

Systemic inflammation caused by COVID-19 may be related to nutrition risk, unfavorable clinical outcomes, and higher mortality in ICU patients. Although the inflammatory marker CRP is the most used in clinical hospital practice, this study showed that NLR was associated with the mNUTRIC score, regardless of sex, age, and BMI. Therefore, it may be interesting to use the systemic inflammatory marker NLR as a complementary tool in the early identification of nutrition risk by performing a more complete nutrition assessment and better prediction of negative clinical outcomes during admission to the ICU in patients with COVID-19.

ACKNOWLEDGMENTS

Gustavo D. Pimentel would like to The Brazilian National Council for Scientific and Technological Development (CNPq, Brazil, 312252/2019-6).

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

Paula M. Martins, Emanoelly P. Franco, Liana L. Vieira, Tatyanne L. N. Gomes, and Gustavo D. Pimentel contributed to the study design. Paula M. Martins and Emanoelly P. Franco participated in the collection data. Paula M. Martin and Tatyanne L. N. Gomes performed the bibliographic research and participated in the discussion of the manuscript. Paula M. Martins, Emanoelly P. Franco, Tatyanne L. N. Gomes, Liana L. Vieira, and Gustavo D. Pimentel wrote the manuscript. All authors participated in the critical discussion of the data, reviewed the manuscript, and read and approved the final version of the article.

ORCID

Gustavo D. Pimentel PhD https://orcid.org/0000-0002-2979-9819

REFERENCES

1. Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192-206.
2. Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc. 2020;68(5):926-929.
3. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):1-12.
4. Anderson EL, Turnham P, Griffin JR, Clarke CC. Consideration of the aerosol transmission for COVID-19 and public health. Risk Anal. 2020;40(5):902-907.
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
6. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
7. Barazzoni R, Bischoff SC, Breda J, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020;39(6):1631-1638.
8. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for disease control and prevention. JAMA. 2020;323(13):1239-1242.
9. Thibault R, Seguin P, Tamion F, Pichard C, Singer P. Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance. Crit Care. 2020;24(1):447.
10. Zabetakis I, Lordan R, Norton C, Toupras A. COVID-19: the inflammation link and the role of nutrition in potential mitigation. Nutrients. 2020;12(5):1466.
11. Tay MZ, Poh CM, Rénia L, Macary PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.
12. Cihakova D, Streiff MB, Menez SP, et al. High-value laboratory testing for hospitalized COVID-19 patients: a review. Future Virol. 2021;10:2217/fviol-2020-0316.
13. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206.
14. Dos Reis AM, Fruchtenicht AVG, Moreira LF. Uso do escore NUTRIC pelo mundo: uma revisão sistemática. Rev Bras Ter Intensiva. 2019;31(3):379-385.
15. Omar M, Eltagi S, Nouh F. Covid-19 and nutrition: review of available evidence. Sch J App Med Sci. 2020;8(4):1158-1164.
16. McClave SA, Taylor BE, Martindale RG, et al; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: society of critical care medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enter Nutr. 2016;40(2):159-211.
17. Li G, Zhou C-L, Ba Y-M, et al. Nutritional risk and therapy for severe and critical COVID-19 patients: a multicenter retrospective observational study. Clin Nutr. 2021;40(4):2154-2161.
18. Zhang P, He Z, Yu G, et al. The modified NUTRIC score can be used for nutritional risk assessment as well as prognosis prediction in critically ill COVID-19 patients. Clin Nutr. 2021;40(2):534-541.

19. Hu Y, Li X, Gong W. Nutritional support for critically ill patients with COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(3):347-355.

20. Ferreira DC, Santos DC, Vieira MP, Sampaio NCS, Andrade SS. Manejo nutricional para pacientes hospitalizados com COVID-19: uma revisão integrativa. Saúde Coletiva (Barueri). 2020;10(59):410-4151.

21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-829.

22. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707-710.

23. Rahman A, Hasan RM, Agarwala R, Martin C, Day AG, Heyland DK. Identifying critically-ill patients who will benefit most from nutritional therapy: further validation of the "modified NUTRIC" nutritional risk assessment tool. Clin Nutr. 2016;35(1):158-162.

24. Physical status: The use and interpretation of anthropometry physical status. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.

25. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.

26. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22(3):321-336.

27. Rahman A, Hasan RM, Agarwala R, Martin C, Day AG, Heyland DK. Identifying critically-ill patients who will benefit most from nutritional therapy: further validation of the "modified NUTRIC" nutritional risk assessment tool. Clin Nutr. 2016;35(1):158-162.

28. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? J Parenter Enteral Nutr. 1987;11(18):13. http://doi.org/10.1177/014860718701100108

29. Canales C, Elsayes A, Yeh DD, et al. Nutrition risk in critically ill versus the nutritional risk screening 2002: are they comparable for assessing risk of malnutrition in critically ill patients? J Parenter Enter Nutr. 2019;43(1):81-87.

30. Lü, Chen C. Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19). Epidemiol Infect. 2020;148:e164.

31. Neto NSR, De Carvalho JF. O uso de provas de atividade inflamatória em reumatologia. Rev Bras Reumatol. 2009;49(4):413-430.

32. Aguiar FBJ, Ferreira-Júnior M, Sales MM, et al. Proteína C reativa: aplicações clínicas e propostas para utilização racional. Rev Assoc Med Bras. 2013;59(1):85-92.

33. Merker M, Felder M, Gueissaz L, et al. Association of baseline inflammation with effectiveness of nutritional support among patients with disease-related malnutrition: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2020;3(3):e200663.

34. Mahmudpour M, Roozbah J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: the anger of inflammation. Cytokine. 2020;133:155151.

35. Cai J, Li H, Zhang C, et al. The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19. Cell Metab. 2021;33(2):258-269.e3.

36. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

37. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020;46(6):1105-1108.

38. Ou M, Zhu J, Ji P, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:x175.

39. Chan AS, Rout A. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448-453.

40. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768.

41. Formisano E, Di Maio P, Ivaldi C, et al. Nutritional therapy for patients with coronavirus disease 2019 (COVID-19): practical protocol from a single center highly affected by an outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nutrition. 2020;82:110148.

42. Alves TCHS, Guimarães RS, Souza SF, et al. Influence of nutritional assistance on mortality by COVID-19 in critically ill patients. Clin Nutr ESPEN. 2021;44:469-471.

43. Pimentel GD, Dela Vega MCM, Laviano A. High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients. Clin Nutr ESPEN. 2020;40:101-102.

44. Pimentel GD, Dela Vega MCM, Laviano A. High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients. Clin Nutr ESPEN. 2020;40:101-102.

45. Sarkar S, Khanna P, Singh AK. The impact of neutrophil-lymphocyte count ratio in covid-19: a systematic review and meta-analysis. J Intensive Care Med. Accepted manuscript. Published online October 21, 2021. https://doi.org/10.1177/08850666211045626

46. Oliveira ML, Heyland DK, Silva FM, et al. Complementarity of modified NUTRIC score with or without C-reactive protein and subjective global assessment in predicting mortality in critically ill patients. Rev Bras Ter Intensiva. 2019;31:490-496.

47. Zeng ZY, Feng SD, Chen GP, Wu JN. Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study. BMC Infect Dis. 2021;21(1):80.

48. Man MA, Rajnoveanu RM, Motoc NS, et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients. PLoS One. 2021;16:e0252599.

49. Song C-Y, Xu J, He J-Q & Lu Y-Q COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients. MedRxiv. Preprint posted online March 8, 2020. https://doi.org/10.1101/2020.03.05.20031906

50. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6-e12.

51. Wei W, Wu X, Jin C, et al. Predictive significance of the prognostic nutritional index (PNI) in patients with severe COVID-19. J Immunol Res. 2021;2021:9917302.